

# Francis MÃ©graud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3583621/publications.pdf>

Version: 2024-02-01

208  
papers

16,028  
citations

25034

57  
h-index

18130

120  
g-index

220  
all docs

220  
docs citations

220  
times ranked

11316  
citing authors

#	ARTICLE	IF	CITATIONS
1	Room for Improvement in the Treatment of <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e98-e108.	2.2	36
2	Systematic Review and Meta-Analysis of Histological Gastric Biopsy Aspects According to the Updated Sydney System in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 13-19.	1.8	8
3	Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for <i>Helicobacter pylori</i> Detection?. <i>Diagnostics</i> , 2022, 12, 133.	2.6	7
4	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). <i>Journal of Clinical Medicine</i> , 2022, 11, 1658.	2.4	13
5	Empirical Second-Line Therapy in 5000 Patients of the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2243-2257.	4.4	15
6	Microbiota and gastric cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 11-17.	9.6	28
7	Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of <i>Helicobacter pylori</i> Infection (Hp-EuReg). <i>Journal of Clinical Medicine</i> , 2022, 11, 3544.	2.4	7
8	European Registry on <i>Helicobacter pylori</i> management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <i>United European Gastroenterology Journal</i> , 2021, 9, 38-46.	3.8	39
9	Classification system for <i>Helicobacter pylori</i> therapies: Compared and contrasted to traditional infectious disease therapy. <i>Helicobacter</i> , 2021, 26, e12773.	3.5	5
10	Survey of the antimicrobial resistance of <i>Helicobacter pylori</i> in France in 2018 and evolution during the previous 5 years. <i>Helicobacter</i> , 2021, 26, e12767.	3.5	15
11	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21%533 patients. <i>Gut</i> , 2021, 70, 40-54.	12.1	139
12	Autophagy induced by <i>Helicobacter pylori</i> infection is necessary for gastric cancer stem cell emergence. <i>Gastric Cancer</i> , 2021, 24, 133-144.	5.3	24
13	Culture-Based Antimicrobial Susceptibility Testing for <i>Helicobacter pylori</i> . <i>Methods in Molecular Biology</i> , 2021, 2283, 45-50.	0.9	6
14	Evaluation of CAMPYLOBACTER QUIK CHEK,¢ rapid membrane enzyme immunoassay to detect <i>Campylobacter</i> spp. antigen in stool samples. <i>Gut Pathogens</i> , 2021, 13, 4.	3.4	4
15	Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3418.	4.1	69
16	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to <i>Clostridioides difficile</i> Infections into the Local Clinical Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 147-163.	0.9	0
17	<i>Helicobacter pylori</i> resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. <i>Gut</i> , 2021, 70, 1815-1822.	12.1	159
18	Adverse Event Profile During the Treatment of <i>Helicobacter pylori</i> : A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , 2021, 116, 1220-1229.	0.4	40

#	ARTICLE	IF	CITATIONS
19	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 495-507.e4.	1.3	89
20	The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 965.	3.7	6
21	Molecular Diagnosis for Helicobacter pylori . . . at Last. <i>Gastroenterology</i> , 2021, 161, 1367-1369.	1.3	0
22	Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013â€“2020: Results of the European Registry on H. pylori Management (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 1058.	3.7	48
23	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. <i>Antibiotics</i> , 2021, 10, 13.	3.7	12
24	Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg). <i>Annals of Gastroenterology</i> , 2021, 35, 42-47.	0.6	3
25	Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database. <i>Therapie</i> , 2021, 76, 435-440.	1.0	0
26	Adaptation of an inâ€“house PCR for the detection of <i>Helicobacter pylori</i> and the mutations associated with macrolide resistance into readyâ€“toâ€“use PCR microwell strips. <i>Helicobacter</i> , 2021, 26, e12855.	3.5	6
27	Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 89-98.	4.4	62
28	The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 257-276.	4.5	46
29	Verteporfin targeting YAP1/TAZâ€“TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells. <i>International Journal of Cancer</i> , 2020, 146, 2255-2267.	5.1	97
30	Alzheimerâ€™s Disease and Helicobacter pylori Infection: Inflammation from Stomach to Brain?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 801-809.	2.6	32
31	Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112.	12.1	239
32	Bismuth quadruple regimen with tetracycline or doxycycline versus threeâ€“inâ€“one single capsule as thirdâ€“line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (Hpâ€“EuReg). <i>Helicobacter</i> , 2020, 25, e12722.	3.5	17
33	Leukaemia Inhibitory Factor (LIF) Inhibits Cancer Stem Cells Tumorigenic Properties through Hippo Kinases Activation in Gastric Cancer. <i>Cancers</i> , 2020, 12, 2011.	3.7	30
34	Helicobacter pylori eradication rates in Slovenia in the period from 2017 to 2019 â€“ data from the European Registry on Helicobacter pylori Management (Hp-EuReg). <i>Digestive Diseases</i> , 2020, 39, 318-324.	1.9	5
35	Review: Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2020, 25, e12735.	3.5	36
36	APRIL-producing eosinophils are involved in gastric MALT lymphomagenesis induced by Helicobacter sp infection. <i>Scientific Reports</i> , 2020, 10, 14858.	3.3	15

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Allplexâ„¢ <i>H pylori</i> and ClariR PCR Assay for <i>Helicobacter pylori</i> detection on gastric biopsies. <i>Helicobacter</i> , 2020, 25, e12702.	3.5	23
38	High Primary Antibiotic Resistance of <i>Helicobacter pylori</i> Strains Isolated from Pediatric and Adult Patients in Poland during 2016â€“2018. <i>Antibiotics</i> , 2020, 9, 228.	3.7	11
39	Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 854.	4.8	8
40	TAZ Controls <i>Helicobacter pylori</i> -Induced Epithelialâ€“Mesenchymal Transition and Cancer Stem Cell-Like Invasive and Tumorigenic Properties. <i>Cells</i> , 2020, 9, 1462.	4.1	29
41	Evaluation of RIDASCREENÂ® and RIDAÂ®QUICK <i>Helicobacter</i> kits for <i>Helicobacter pylori</i> detection in stools. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1941-1943.	2.9	3
42	The Nuclear Remodeling Induced by <i>Helicobacter</i> Cytotoxic Distending Toxin Involves MAFB Oncoprotein. <i>Toxins</i> , 2020, 12, 174.	3.4	7
43	<i>Helicobacter pylori</i> firstâ€line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on Hâpylori management (Hpâ€Reg). <i>Helicobacter</i> , 2020, 25, e12686.	3.5	27
44	Occurrence and Antibiotic Resistance of <i>Arcobacter</i> Species Isolates from Poultry in Tunisia. <i>Journal of Food Protection</i> , 2020, 83, 2080-2086.	1.7	9
45	Title is missing!. , 2020, 15, e0237515.		0
46	Title is missing!. , 2020, 15, e0237515.		0
47	Title is missing!. , 2020, 15, e0237515.		0
48	Title is missing!. , 2020, 15, e0237515.		0
49	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hpâ€Reg). <i>Helicobacter</i> , 2019, 24, e12630.	3.5	46
50	Review: Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2019, 24, e12641.	3.5	52
51	Prevalence of <i>Helicobacter pylori</i> infection and antibiotic resistance profile in Armenia. <i>Gut Pathogens</i> , 2019, 11, 28.	3.4	7
52	Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. <i>Drug Safety</i> , 2019, 42, 993-1003.	3.2	12
53	Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. <i>Cancers</i> , 2019, 11, 560.	3.7	10
54	Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European <i>Helicobacter</i> and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. <i>Endoscopy</i> , 2019, 51, 365-388.	1.8	587

#	ARTICLE	IF	CITATIONS
55	Whole-Genome Sequencing and Bioinformatics as Pertinent Tools to Support Helicobacteraceae Taxonomy, Based on Three Strains Suspected to Belong to Novel Helicobacter Species. <i>Frontiers in Microbiology</i> , 2019, 10, 2820.	3.5	6
56	UEG Activity Grant used to implement guidelines in Armenia. <i>United European Gastroenterology Journal</i> , 2019, 7, 987-987.	3.8	1
57	<i>Campylobacter armoricus</i> sp. nov., a novel member of the <i>Campylobacter lari</i> group isolated from surface water and stools from humans with enteric infection. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2019, 69, 3969-3979.	1.7	17
58	Evaluation of the Diagnostic Accuracy of Two Immunochromatographic Tests Detecting <i>Campylobacter</i> in Stools and Their Role in <i>Campylobacter</i> Infection Diagnosis. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	9
59	A representative overview of the genetic diversity and lipooligosaccharide sialylation in <i>Campylobacter jejuni</i> along the broiler production chain in France and its comparison with human isolates. <i>International Journal of Food Microbiology</i> , 2018, 274, 20-30.	4.7	9
60	New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2018, 33, 263-274.	5.7	36
61	Gastroenterology today: between certainties and news. <i>Minerva Gastroenterologica E Dietologica</i> , 2018, 64, 323-332.	2.2	11
62	Metformin can inhibit <i>Helicobacter pylori</i> growth. <i>Future Microbiology</i> , 2018, 13, 1575-1583.	2.0	13
63	Antibiotic Resistance Is the Key Element in Treatment of <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2018, 155, 1300-1302.	1.3	18
64	Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2018, 23, e12515.	3.5	28
65	Real-time PCR for <i>Helicobacter pylori</i> diagnosis. The best tools available. <i>Helicobacter</i> , 2018, 23, e12512.	3.5	36
66	Molecular detection of mutations involved in <i>Helicobacter pylori</i> antibiotic resistance in Algeria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2034-2038.	3.0	26
67	A GWAS on <i>Helicobacter pylori</i> strains points to genetic variants associated with gastric cancer risk. <i>BMC Biology</i> , 2018, 16, 84.	3.8	55
68	Impact of the introduction of a nucleic acid amplification test for <i>Clostridium difficile</i> diagnosis on stool rejection policies. <i>Gut Pathogens</i> , 2018, 10, 19.	3.4	0
69	A new kit to detect <i>Campylobacter</i> species in stool specimens: the Orion GenRead <i>Campylobacter</i> ®. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1585-1587.	2.9	2
70	Genomic structure and insertion sites of <i>Helicobacter pylori</i> prophages from various geographical origins. <i>Scientific Reports</i> , 2017, 7, 42471.	3.3	34
71	Joint ESPGHAN/NASPGHAN Guidelines for the Management of <i>Helicobacter pylori</i> in Children and Adolescents (Update 2016). <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 991-1003.	1.8	328
72	A New Animal Model of Gastric Lymphomagenesis. <i>American Journal of Pathology</i> , 2017, 187, 1473-1484.	3.8	16

#	ARTICLE	IF	CITATIONS
73	Phylogeographic agreement between prophage and bacterial housekeeping genes in <i>Helicobacter pylori</i> strains from The Gambia. <i>Helicobacter</i> , 2017, 22, e12394.	3.5	10
74	The Irish <i>Helicobacter pylori</i> Working Group consensus for the diagnosis and treatment of <i>H. pylori</i> infection in adult patients in Ireland. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 552-559.	1.6	29
75	Prevalence, antibiotic resistance, and <i>MLST</i> typing of <i>Helicobacter pylori</i> in Algiers, Algeria. <i>Helicobacter</i> , 2017, 22, e12446.	3.5	14
76	Metformin targets gastric cancer stem cells. <i>European Journal of Cancer</i> , 2017, 84, 193-201.	2.8	79
77	Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2017, 22, e12404.	3.5	14
78	Time to change approaches to <i>Helicobacter pylori</i> management. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 692-693.	8.1	8
79	Distinct <i>Campylobacter fetus</i> lineages adapted as livestock pathogens and human pathobionts in the intestinal microbiota. <i>Nature Communications</i> , 2017, 8, 1367.	12.8	56
80	Curved and Spiral Bacilli. , 2017, , 1600-1610.e2.		2
81	Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 1586-1597.	7.0	117
82	<i>Helicobacter pylori</i> treatment results in Slovenia in the period 2013-2015 as a part of European Registry on <i>Helicobacter pylori</i> Management. <i>Radiology and Oncology</i> , 2017, 52, 1-6.	1.7	9
83	<i>Helicobacter pylori</i> Strains and Gastric MALT Lymphoma. <i>Toxins</i> , 2017, 9, 132.	3.4	50
84	Deregulation of MicroRNAs in Gastric Lymphomagenesis Induced in the d3Tx Mouse Model of <i>Helicobacter pylori</i> Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 185.	3.9	14
85	The Cytolethal Distending Toxin Subunit CdtB of <i>Helicobacter hepaticus</i> Promotes Senescence and Endoreplication in Xenograft Mouse Models of Hepatic and Intestinal Cell Lines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 268.	3.9	37
86	A Potential New Human Pathogen Belonging to <i>Helicobacter</i> Genus, Identified in a Bloodstream Infection. <i>Frontiers in Microbiology</i> , 2017, 8, 2533.	3.5	10
87	Isolation and Identification of <i>Campylobacter</i> spp. from Poultry and Poultry By-Products in Tunisia by Conventional Culture Method and Multiplex Real-Time PCR. <i>Journal of Food Protection</i> , 2017, 80, 1623-1627.	1.7	8
88	Prevalence of faecal carriage of colistin-resistant Gram-negative rods in a university hospital in western France, 2016. <i>Journal of Medical Microbiology</i> , 2017, 66, 842-843.	1.8	24
89	Antimicrobial Resistance in <i>Helicobacter</i> and <i>Campylobacter</i> . , 2017, , 991-1006.		0
90	Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant <i>Helicobacter pylori</i> . <i>Frontiers in Microbiology</i> , 2016, 7, 2015.	3.5	19

#	ARTICLE	IF	CITATIONS
91	Failed Eradication for <i>Helicobacter pylori</i> . What Should Be Done? Digestive Diseases, 2016, 34, 505-509.	1.9	10
92	<i>Helicobacter pylori</i> Infection in Children. , 2016, , 443-467.		1
93	The history of <i>Helicobacter pylori</i> : from phylogeography to paleomicrobiology. Clinical Microbiology and Infection, 2016, 22, 922-927.	6.0	30
94	Diagnostic of <i>Helicobacter pylori</i> infection. Helicobacter, 2016, 21, 8-13.	3.5	24
95	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. The Cochrane Library, 2016, , CD009034.	2.8	35
96	<i>Helicobacter pylori</i> resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clinical Microbiology and Infection, 2016, 22, 715-718.	6.0	62
97	Towards effective empirical treatment for <i>Helicobacter pylori</i> eradication. Lancet, The, 2016, 388, 2325-2326.	13.7	4
98	Outbreak in newborns of methicillin-resistant <i>Staphylococcus aureus</i> related to the sequence type 5 Geraldine clone. American Journal of Infection Control, 2016, 44, e9-e11.	2.3	15
99	The GyrA encoded gene: A pertinent marker for the phylogenetic revision of <i>Helicobacter</i> genus. Systematic and Applied Microbiology, 2016, 39, 77-87.	2.8	25
100	The Cytolethal Distending Toxin Subunit CdtB of <i>Helicobacter</i> Induces a Th17-related and Antimicrobial Signature in Intestinal and Hepatic Cells In Vitro. Journal of Infectious Diseases, 2016, 213, 1979-1989.	4.0	24
101	The 5300-year-old <i>Helicobacter pylori</i> genome of the Iceman. Science, 2016, 351, 162-165.	12.6	200
102	Deletion of IQGAP1 promotes <i>Helicobacter pylori</i> -induced gastric dysplasia in mice and acquisition of cancer stem cell properties <i>in vitro</i> . Oncotarget, 2016, 7, 80688-80699.	1.8	20
103	Regulatory T cells may participate in <i>Helicobacter pylori</i> persistence in gastric MALT lymphoma: lessons from an animal model. Oncotarget, 2016, 7, 3394-3402.	1.8	20
104	Synopsis of Antimicrobial Resistance. , 2016, , 371-378.		0
105	Epidemiology and Diagnosis of <i>Helicobacter pylori</i> infection. Helicobacter, 2015, 20, 1-7.	3.5	229
106	An Eighteen-Month <i>Helicobacter</i> Infection Does Not Induce Amyloid Plaques or Neuroinflammation in Brains of Wild Type C57BL/6J Mice. Journal of Alzheimer's Disease, 2015, 45, 1045-1050.	2.6	13
107	EUCAST recommendations for antimicrobial susceptibility testing applied to the three main <i>Campylobacter</i> species isolated in humans. Journal of Microbiological Methods, 2015, 119, 206-213.	1.6	50
108	Molecular Detection of <i>Helicobacter pylori</i> and its Antimicrobial Resistance in Brazzaville, Congo. Helicobacter, 2015, 20, 316-320.	3.5	45



#	ARTICLE	IF	CITATIONS
109	Community Incidence of Campylobacteriosis and Nontyphoidal Salmonellosis, France, 2008â€“2013. <i>Foodborne Pathogens and Disease</i> , 2015, 12, 664-669.	1.8	23
110	Molecular Approaches to Identify <i>Helicobacter pylori</i> Antimicrobial Resistance. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 577-596.	2.2	42
111	Epidemiology of <i>Helicobacter pylori</i> and Mechanisms of Carcinogenesis. , 2015, , 171-179.		0
112	Characterisation of inflammatory processes in <i>Helicobacter pylori</i> -induced gastric lymphomagenesis in a mouse model. <i>Oncotarget</i> , 2015, 6, 34525-34536.	1.8	11
113	Antimicrobial susceptibility of <i>Helicobacter pylori</i> isolates from Lower Silesia, Poland. <i>Archives of Medical Science</i> , 2014, 3, 505-509.	0.9	25
114	<i>Helicobacter pullorum</i> Cytolethal Distending Toxin Targets Vinculin and Cortactin and Triggers Formation of Lamellipodia in Intestinal Epithelial Cells. <i>Journal of Infectious Diseases</i> , 2014, 209, 588-599.	4.0	33
115	<i> <i>Helicobacter pylori</i> Helicobacter, 2014, 19, 26-36.	3.5	19
116	Diagnosis of <i> <i>Helicobacter pylori</i> Helicobacter, 2014, 19, 6-10.	3.5	14
117	Role of <i>Campylobacter jejuni</i> gamma-glutamyl transpeptidase on epithelial cell apoptosis and lymphocyte proliferation. <i>Gut Pathogens</i> , 2014, 6, 20.	3.4	14
118	Neonatal Thymectomy Favors <i>Helicobacter pylori</i> â€“Promoted Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Lesions in BALB/c Mice. <i>American Journal of Pathology</i> , 2014, 184, 2174-2184.	3.8	20
119	Diagnosis and Epidemiology of <i> <i>Helicobacter pylori</i> Helicobacter, 2013, 18, 5-11.	3.5	114
120	Infection Ã <i>Helicobacter pylori</i> et cancer gastrique. <i>Revue Francophone Des Laboratoires</i> , 2013, 2013, 67-76.	0.0	4
121	<i> <i>Helicobacter pylori</i> Gut, 2013, 62, 34-42.	12.1	743
122	Hepatic Lesions Observed in Hepatitis <sc>C</sc> Virus Transgenic Mice Infected by <i> <i>Helicobacter hepaticus</i> Helicobacter, 2013, 18, 33-40.	3.5	11
123	Does <i> <i>Helicobacter pylori</i> Personnes AgÃ©es <sc>QUID</sc> Study. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 74-78.	2.6	48
124	Current recommendations for <i>Helicobacter pylori</i> therapies in a world of evolving resistance. <i>Gut Microbes</i> , 2013, 4, 541-548.	9.8	41
125	Inflammatory cytokine and microRNA responses of primary human dendritic cells cultured with <i>Helicobacter pylori</i> strains. <i>Frontiers in Microbiology</i> , 2013, 4, 236.	3.5	31
126	Comparative Evaluation of 29 Commercial <i> <i>Helicobacter pylori</i> Helicobacter, 2013, 18, 169-179.	3.5	97



#	ARTICLE	IF	CITATIONS
127	The challenge of <i>Helicobacter pylori</i> resistance to antibiotics: the comeback of bismuth-based quadruple therapy. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 103-109.	3.2	109
128	Epidemiology and Diagnosis of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2012, 17, 1-8.	3.5	115
129	Impact of chronic <i>Helicobacter pylori</i> infection on Alzheimer's disease: preliminary results. <i>Neurobiology of Aging</i> , 2012, 33, 1009.e11-1009.e19.	3.1	108
130	Evaluation of the positive predictive value of a rapid Immunochromatographic test to detect <i>Campylobacter</i> in stools. <i>Gut Pathogens</i> , 2012, 4, 17.	3.4	16
131	<i>Helicobacter pylori</i> Infection Recruits Bone Marrow-Derived Cells That Participate in Gastric Preneoplasia in Mice. <i>Gastroenterology</i> , 2012, 142, 281-291.	1.3	125
132	Management of <i>Helicobacter pylori</i> infection—the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012, 61, 646-664.	12.1	2,023
133	The most important diagnostic modalities for <i>Helicobacter pylori</i> , now and in the future. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 9 Suppl 1, S13-5; discussion S15.	1.6	5
134	Genome Sequencing Reveals a Phage in <i>Helicobacter pylori</i> . <i>MBio</i> , 2011, 2, .	4.1	60
135	<i>Helicobacter pylori</i> molecular diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 351-355.	3.1	21
136	<i>Helicobacter pylori</i> eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet, The</i> , 2011, 377, 905-913.	13.7	458
137	Evidence-based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 53, 230-243.	1.8	269
138	DPO multiplex PCR as an alternative to culture and susceptibility testing to detect <i>Helicobacter pylori</i> and its resistance to clarithromycin. <i>BMC Gastroenterology</i> , 2011, 11, 112.	2.0	69
139	New Methods for Detection of <i>Campylobacters</i> in Stool Samples in Comparison to Culture. <i>Journal of Clinical Microbiology</i> , 2011, 49, 941-944.	3.9	106
140	Human Bone Marrow-Derived Stem Cells Acquire Epithelial Characteristics through Fusion with Gastrointestinal Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e19569.	2.5	94
141	<i>Helicobacter pylori</i> Infection of Gastrointestinal Epithelial Cells in vitro Induces Mesenchymal Stem Cell Migration through an NF- $\kappa$ B-Dependent Pathway. <i>PLoS ONE</i> , 2011, 6, e29007.	2.5	53
142	Sequential Therapy for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 313-325.	2.2	194
143	From array-based hybridization of <i>Helicobacter pylori</i> isolates to the complete genome sequence of an isolate associated with MALT lymphoma. <i>BMC Genomics</i> , 2010, 11, 368.	2.8	47
144	Clinical Relevance and Diversity of Two Homologous Genes Encoding Glycosyltransferases in <i>Helicobacter pylori</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 2885-2891.	3.9	35

#	ARTICLE	IF	CITATIONS
145	Complexomics Study of Two <i>Helicobacter pylori</i> Strains of Two Pathological Origins. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2796-2826.	3.8	22
146	Curved and spiral bacilli. , 2010, , 1728-1737.		1
147	Is There a Link between the Lipopolysaccharide of <i>Helicobacter pylori</i> Gastric MALT Lymphoma Associated Strains and Lymphoma Pathogenesis?. <i>PLoS ONE</i> , 2009, 4, e7297.	2.5	12
148	Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance in <i>Helicobacter pylori</i> . <i>Journal of Clinical Microbiology</i> , 2009, 47, 3600-3607.	3.9	151
149	Allelic diversity and phylogeny of homB, a novel co-virulence marker of <i>Helicobacter pylori</i> . <i>BMC Microbiology</i> , 2009, 9, 248.	3.3	32
150	Disease association with two <i>Helicobacter pylori</i> duplicate outer membrane protein genes, homB and homA. <i>Gut Pathogens</i> , 2009, 1, 12.	3.4	46
151	Diagnosis of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2008, 13, 7-12.	3.5	22
152	<i>Helicobacter</i> species and liver diseases: association or causation?. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 254-260.	9.1	124
153	Evaluation of the Clinical Significance of <i>homB</i> , a Novel Candidate Marker of <i>Helicobacter pylori</i> Strains Associated with Peptic Ulcer Disease. <i>Journal of Infectious Diseases</i> , 2008, 198, 1379-1387.	4.0	71
154	<i>Helicobacter pylori</i> and antibiotic resistance. <i>Gut</i> , 2007, 56, 1502-1502.	12.1	94
155	<i>Helicobacter pylori</i> Detection and Antimicrobial Susceptibility Testing. <i>Clinical Microbiology Reviews</i> , 2007, 20, 280-322.	13.6	595
156	Current management of <i>Helicobacter pylori</i> infections in the elderly. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 845-856.	4.4	19
157	Eradication Therapy for <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2007, 133, 985-1001.	1.3	217
158	Update on fluoroquinolone resistance in <i>Helicobacter pylori</i> : new mutations leading to resistance and first description of a <i>gyrA</i> polymorphism associated with hypersusceptibility. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 389-396.	2.5	90
159	Detection of <i>Helicobacter pylori</i> and its sensitivity to antibiotics. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 790.	0.9	3
160	<i>In Vitro</i> Proinflammatory Properties of <i>Helicobacter pylori</i> Strains Causing Low-Grade Gastric MALT Lymphoma. <i>Helicobacter</i> , 2007, 12, 616-617.	3.5	10
161	Evolution of <i>Helicobacter pylori</i> Research as Observed Through the Workshops of the European <i>Helicobacter</i> Study Group. <i>Helicobacter</i> , 2007, 12, 1-5.	3.5	138
162	Is <i>Helicobacter pylori</i> a True Microaerophile?. <i>Helicobacter</i> , 2006, 11, 296-303.	3.5	55

#	ARTICLE	IF	CITATIONS
163	Helicobacter pylori infection relapse after eradication is not a problem in developed countries. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 484-485.	1.7	2
164	Identification of Markers for Helicobacter pylori Strains Isolated from Children with Peptic Ulcer Disease by Suppressive Subtractive Hybridization. Infection and Immunity, 2006, 74, 4064-4074.	2.2	54
165	Evaluation of the Homologous Recombination in Helicobacter pylori. Helicobacter, 2005, 10, 185-192.	3.5	6
166	Diagnosis of Helicobacter pylori Infection. Helicobacter, 2005, 10, 5-13.	3.5	53
167	Update on therapeutic options for Helicobacter pylori-related diseases. Current Infectious Disease Reports, 2005, 7, 115-120.	3.0	25
168	Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. Journal of Antimicrobial Chemotherapy, 2005, 56, 491-497.	3.0	68
169	Helicobacter pylori Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique. American Journal of Gastroenterology, 2005, 100, 2100-2115.	0.4	202
170	Pathogen Evolution In Vivo: Genome Dynamics of Two Isolates Obtained 9 Years Apart from a Duodenal Ulcer Patient Infected with a Single Helicobacter pylori Strain. Journal of Clinical Microbiology, 2005, 43, 4237-4241.	3.9	39
171	Campylobacter. Veterinary Research, 2005, 36, 351-382.	3.0	389
172	Comparison of non-invasive tests to detect Helicobacter pylori infection in children and adolescents: Results of a multicenter European study. Journal of Pediatrics, 2005, 146, 198-203.	1.8	118
173	A Humble Bacterium Sweeps This Year's Nobel Prize. Cell, 2005, 123, 975-976.	28.9	47
174	Evaluation of the Association of Nine Helicobacter pylori Virulence Factors with Strains Involved in Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Infection and Immunity, 2004, 72, 880-888.	2.2	107
175	Helicobacter pylori and gastric cancer prevention is possible. Cancer Detection and Prevention, 2004, 28, 392-398.	2.1	13
176	Diagnosis of Helicobacter pylori Infection. Helicobacter, 2004, 9, 7-14.	3.5	40
177	Basis for the Management of Drug-Resistant Helicobacter pylori Infection. Drugs, 2004, 64, 1893-1904.	10.9	65
178	Expression and activity of the cytolethal distending toxin of Helicobacter hepaticus. Biochemical and Biophysical Research Communications, 2004, 318, 739-745.	2.1	47
179	Diagnosis of Helicobacter pylori infection. Helicobacter, 2003, 8, 13-20.	3.5	34
180	Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Research in Microbiology, 2003, 154, 137-144.	2.1	71

#	ARTICLE	IF	CITATIONS
181	Traces of Human Migrations in <i>Helicobacter pylori</i> Populations. <i>Science</i> , 2003, 299, 1582-1585.	12.6	922
182	Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in <i>Helicobacter pylori</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 397-402.	3.9	206
183	New Pathogenicity Marker Found in the Plasticity Region of the <i>Helicobacter pylori</i> Genome. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1651-1655.	3.9	64
184	Which test to use to detect <i>Helicobacter pylori</i> infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma?. <i>American Journal of Gastroenterology</i> , 2003, 98, 291-295.	0.4	73
185	<i>Helicobacter pylori</i> Resistance to Antibiotics: Prevalence, Mechanism, Detection. What's New?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 49B-52B.	1.7	14
186	In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of <i>Helicobacter pylori</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 865-872.	3.0	22
187	PCR-Restriction Fragment Length Polymorphism Can Also Detect Point Mutation A2142C in the 23S rRNA Gene, Associated with <i>Helicobacter pylori</i> Resistance to Clarithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1156-1157.	3.2	70
188	Is the molecular basis of metronidazole resistance in microaerophilic organisms understood?. <i>Trends in Microbiology</i> , 2002, 10, 370-375.	7.7	59
189	Detecting <i>Helicobacter Pylori</i> Infection in Hospitalized Frail Older Patients: The Challenge. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1674-1680.	2.6	25
190	Epidemiology and diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2002, 7, 8-16.	3.5	70
191	Resistance of <i>Helicobacter pylori</i> to antibiotics and its impact on treatment options. <i>Drug Resistance Updates</i> , 2001, 4, 178-186.	14.4	45
192	Detection of <i>Helicobacter pylori</i> DNA in human feces by PCR: DNA stability and removal of inhibitors. <i>Journal of Microbiological Methods</i> , 2001, 45, 89-94.	1.6	80
193	Impact of <i>Helicobacter pylori</i> ; Virulence on the Outcome of Gastroduodenal Diseases: Lessons from the Microbiologist. <i>Digestive Diseases</i> , 2001, 19, 99-103.	1.9	25
194	<i>Helicobacter pylori</i> infection in patients consulting gastroenterologists in France: prevalence is linked to gender and region of residence. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 677-684.	1.6	25
195	Magnetic Immuno-PCR Assay with Inhibitor Removal for Direct Detection of <i>Helicobacter pylori</i> in Human Feces. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3778-3780.	3.9	35
196	Detection of <i>Helicobacter</i> species in the liver of patients with and without primary liver carcinoma. <i>Cancer</i> , 2000, 89, 1431-1439.	4.1	125
197	The HOMER Study: The Effect of Increasing the Dose of Metronidazole When Given with Omeprazole and Amoxicillin to Cure <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2000, 5, 196-201.	3.5	78
198	Ranitidine Bismuth Citrate Can Help to Overcome <i>Helicobacter pylori</i> Resistance to Clarithromycin In Vivo. <i>Helicobacter</i> , 2000, 5, 222-226.	3.5	25

#	ARTICLE	IF	CITATIONS
199	Strategies to treat patients with antibiotic resistant <i>Helicobacter pylori</i> . International Journal of Antimicrobial Agents, 2000, 16, 507-509.	2.5	16
200	Detection of <i>Helicobacter</i> species in the liver of patients with and without primary liver carcinoma. Cancer, 2000, 89, 1431-1439.	4.1	1
201	Diagnosis of <i>Helicobacter pylori</i> infection with a new non-invasive antigen-based assay. Lancet, The, 1999, 354, 30-33.	13.7	375
202	Geographic distribution of <i>vacA</i> allelic types of <i>Helicobacter pylori</i> . Gastroenterology, 1999, 116, 823-830.	1.3	412
203	The MACH2 study: Role of omeprazole in eradication of <i>Helicobacter pylori</i> with 1-week triple therapies. Gastroenterology, 1999, 116, 248-253.	1.3	405
204	Heterogeneity of Immunoglobulin G Response to <i>Helicobacter pylori</i> Measured by the Unweighted Pair Group Method with Averages. Vaccine Journal, 1998, 5, 70-73.	2.6	11
205	How Should <i>Helicobacter pylori</i> Infection Be Diagnosed?. Gastroenterology, 1997, 113, S93-S98.	1.3	98
206	<i>Helicobacter pylori</i> and duodenal ulcer. Digestive Diseases and Sciences, 1992, 37, 769-772.	2.3	158
207	Activity of lansoprazole against <i>Helicobacter pylori</i> . Lancet, The, 1991, 337, 1486.	13.7	109
208	Gastric Cancer: A Stem Cell Disease?. , 0, , .		2